Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)- 1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: relationship between urinary biomarkers and oral leukoplakia.

Two metabolites of the carcinogenic tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone were quantified in the urine of smokeless tobacco users. The metabolites are 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanol (NNAL) and [4-(methylnitrosamino)-1-(3-pyridyl) but-1-yl]-beta-O-D-glucosiduronic acid (NNAL-Gluc). The study population consisted of 47 male nonsmokers, of whom 23 were snuff dippers, 13 were tobacco chewers, 3 were users of both products, and 8 were nonusers. The levels of NNAL-Gluc in urine ranged from 0.14-30.3 pmol/mg creatinine with a mean +/- SD of 3.47 +/- 5.86, whereas the levels of NNAL ranged from 0.02-8.73 pmol/mg creatinine with a mean +/- SD of 0.92 +/- 1.59. The mean levels of NNAL-Gluc and NNAL were not significantly different from those measured in a previous study of smokers. The levels of NNAL-Gluc were significantly higher in snuff dippers than in tobacco chewers. The ratio of NNAL-Gluc:NNAL was higher in snuff dippers than in tobacco chewers or smokers. There was no indication of two phenotypes of the NNAL-Gluc:NNAL ratio in smokeless tobacco users, in contrast to previous observations in smokers. Of the 39 smokeless tobacco users in this study, 16 presented with oral leukoplakia. When the total levels of NNAL-Gluc, NNAL, or NNAL-Gluc + NNAL were divided into tertiles, there was a significant association between the presence of leukoplakia and increasing levels of these metabolites; a similar relationship was found between urinary cotinine and leukoplakia. The results of this study demonstrate that there is significant uptake of carcinogenic nitrosamines in smokeless tobacco users, and that such products are not harmless alternatives to cigarettes. Moreover, the urinary biomarkers NNAL-Gluc, NNAL, and cotinine were associated with the presence of leukoplakia, which provides biochemical support for the role of smokeless tobacco products as a cause of oral leukoplakia.

[1]  S. Hecht,et al.  Intraindividual and interindividual differences in metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers' urine. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  S. Amin,et al.  Improved methodology for the quantitative assessment of tobacco-specific N-nitrosamines in tobacco by supercritical fluid extraction , 1995 .

[3]  G. Andersson,et al.  Oral mucosal changes and nicotine disposition in users of Swedish smokeless tobacco products: a comparative study. , 1994, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[4]  M. Djordjevic,et al.  Tobacco-specific N-nitrosamines and Areca-derived N-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. , 1994, Journal of toxicology and environmental health.

[5]  S. Hecht,et al.  Metabolites of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers' urine. , 1993, Cancer research.

[6]  L. Anderson,et al.  Metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the patas monkey: pharmacokinetics and characterization of glucuronide metabolites. , 1993, Carcinogenesis.

[7]  H. Bartsch,et al.  Carcinogenic tobacco-specific nitrosamines are present at unusually high levels in the saliva of oral snuff users in Sudan. , 1992, Carcinogenesis.

[8]  H. Stich,et al.  Localized formation of micronuclei in the oral mucosa and tobacco‐specific nitrosamines in the saliva of “reverse” smokers, khaini‐tobacco chewers and gudakhu users , 1992, International journal of cancer.

[9]  D. Hoffmann,et al.  A study of betel quid carcinogenesis. IX. Comparative carcinogenicity of 3-(methylnitrosamino)propionitrile and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone upon local application to mouse skin and rat oral mucosa. , 1991, Cancer letters.

[10]  J. Miners,et al.  Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.

[11]  S. Amin,et al.  Characterization of a glucuronide metabolite of 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its dose-dependent excretion in the urine of mice and rats. , 1990, Carcinogenesis.

[12]  S. Hecht,et al.  Mass spectrometric analysis of tobacco-specific nitrosamine hemoglobin adducts in snuff dippers, smokers, and nonsmokers. , 1990, Cancer research.

[13]  B. Gerbert,et al.  Smokeless tobacco use and health effects among baseball players. , 1990, JAMA.

[14]  V. Ernster,et al.  Oral mucosal lesions found in smokeless tobacco users. , 1990, Journal of the American Dental Association.

[15]  M. Nair,et al.  Chemopreventive trials with vitamin A and β-carotene: Some unresolved issues , 1989 .

[16]  M. Djordjevic,et al.  Identification and analysis of a nicotine-derived N-nitrosamino acid and other nitrosamino acids in tobacco. , 1989, Carcinogenesis.

[17]  N. Benowitz,et al.  Daily use of smokeless tobacco: systemic effects. , 1989, Annals of internal medicine.

[18]  John D. Adams,et al.  Analyses of steam distillates and aqueous extracts of smokeless tobacco , 1989 .

[19]  Magee Pn.  The experimental basis for the role of nitroso compounds in human cancer. , 1989 .

[20]  D Hoffmann,et al.  The relevance of tobacco-specific nitrosamines to human cancer. , 1989, Cancer surveys.

[21]  S. Preston‐Martin,et al.  Epidemiological evidence for the role of nitroso compounds in human cancer. , 1989, Cancer surveys.

[22]  S. Amin,et al.  Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. , 1988, Cancer research.

[23]  B. Österdahl,et al.  Tobacco-specific N-nitrosamines in the saliva of habitual male snuff dippers. , 1988, Food additives and contaminants.

[24]  H. Stich,et al.  Tobacco-specific nitrosamines in the saliva of Inuit snuff dippers in the Northwest Territories of Canada. , 1987, Cancer letters.

[25]  S. Hecht,et al.  Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. , 1986, Cancer research.

[26]  J. Adams,et al.  Snuff-dipping in college students: a clinical profile. , 1986, Military medicine.

[27]  B. Spiegelhalder,et al.  N-nitrosamines in the saliva of tobacco chewers or masheri users. , 1986, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  H. Bartsch,et al.  Tobacco-specific and betel nut-specific N-nitroso compounds: occurrence in saliva and urine of betel quid chewers and formation in vitro by nitrosation of betel quid. , 1985, Carcinogenesis.

[29]  N. Haley,et al.  Validation of self-reported smoking behavior: biochemical analyses of cotinine and thiocyanate. , 1983, American journal of public health.

[30]  S. Hecht,et al.  Comparative carcinogenicity in A/J mice and metabolism by cultured mouse peripheral lung of N'-nitrosonornicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, and their analogues. , 1983, Cancer research.

[31]  L. Tremaine,et al.  Salicylate enhancement of renal glucuronide conjugation and tubular excretory transfer of phenols. , 1982, Drug Metabolism And Disposition.

[32]  J. Adams,et al.  Carcinogenic tobacco-specific N-nitrosamines in snuff and in the saliva of snuff dippers. , 1981, Cancer research.

[33]  Nathan Mantel,et al.  Chi-square tests with one degree of freedom , 1963 .